Considering the potential impact of the "Human Brain Mapping Project", the investment to date of approximately $35,000,000 in developing the patented MANF technology, and the value attached to Amarantus Diagnostics, and the fact that the GDNF technology sold for $265,000,000 I would attach a current value to Amarantus Bioscience in the $100,000,000 range or about .45/share.
I'm looking forward to Jason Napadano's valuation.
p.s. I'm being very conservative in my approach.
Joint venture or development partnership with a "big pharma" drug company would be the best move for the company.
The partner could cover the cost of developing the MANF technology into marketable drugs and an upfront cash payment could fund the development of the diagnostic tests by the company.
Time will reveal all.
p.s. This is substantially undervalued.